Psoriatic arthritis (PsA) patients who also qualified for a diagnosis of metabolic syndrome were far more likely to meet ...

The global Psoriatic Arthritis (PsA) Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Psoriatic arthritis affects more than two million people in the U.S. Find out more about the prevalence of psoriatic arthritis and other key statistics. ... Signs It’s Time to Switch Psoriatic ...

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Clinic Case in Psoriatic Arthritis: Guided Steps in Treatment Selection 0.25 CME / ABIM MOC Credits Clinical Case You are being redirected to Medscape Education Yes, take me there ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Psoriatic arthritis a form of inflammatory arthritis that occurs with psoriasis, a skin condition that shows up as a red scaly, sometime itchy rash that typically occurs over the knees, elbows and ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...